Why the study?
Anticancer therapies and cancer itself can induce pro-arrhythmic cardiotoxicity, making it crucial to recognize these risks and know how to manage resulting arrhythmias.
Provides an overview of the epidemiology, risk factors, and management of cardiac arrhythmias in oncology patients, emphasizing the cardiotoxicity of novel therapies.
Supports heightened arrhythmia surveillance during novel anticancer therapy; leaves open the need for prospective trials to guide management.
One of the side effects of different chemotherapeutics is their pro-arrhythmic activity. Both atrial and ventricular arrhythmias may be induced by cancer itself or by anticancer treatment. Recent studies report on the cardiotoxic activity of such promising therapies as BRAF and MEK inhibitors, or CAR-T therapy. Risk factors of arrhythmias in oncological patients overlap with cardiovascular diseases risk factors, but there are some groups of anticancer drugs that increase the risk of cardiotoxicity. It is crucial to be aware of the risks associated with the oncological treatment and know how to act in case of cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Gawlik et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: